Evidence map›Paper›PMID 32412693›Full record

ArticleThe oncologist2020

Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak.

Giulia Viale, Luca Licata, Lorenzo Sica, Stefania Zambelli, Patrizia Zucchinelli, Alessia Rognone, Daniela Aldrighetti, Rosa Di Micco, Veronica Zuber, Marcella Pasetti and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Psychological Distress in Breast Cancer Patients during the Italian COVID-19 Pandemic.International journal of environmental research and public health · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Radiotherapy during the COVID-19: a review about management and treatment strategies.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Review
  17. Article
  18. Review
  19. Cancer therapy and treatments during COVID-19 era.Advances in biological regulation · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Giulia Viale *Breast Cancer Group, Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Luca Licata *Breast Cancer Group, Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.ORCID 0000-0002-0331-3585
Lorenzo SicaBreast Cancer Group, Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Stefania ZambelliBreast Cancer Group, Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Patrizia ZucchinelliBreast Cancer Group, Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Alessia RognoneBreast Cancer Group, Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Daniela AldrighettiBreast Cancer Group, Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Rosa Di MiccoBreast Surgery Unit, IRCCS San Raffaele Hospital, Milan, Italy.
Veronica ZuberBreast Surgery Unit, IRCCS San Raffaele Hospital, Milan, Italy.
Marcella PasettiRadiotherapy Unit, IRCCS San Raffaele Hospital, Milan, Italy.
Nadia Di MuzioRadiotherapy Unit, IRCCS San Raffaele Hospital, Milan, Italy.
Mariagrazia RodighieroBreast Imaging Unit, IRCCS San Raffaele Hospital, Milan, Italy.
Pietro PanizzaBreast Imaging Unit, IRCCS San Raffaele Hospital, Milan, Italy.
Isabella SassiPathology Unit, IRCCS San Raffaele Hospital, Milan, Italy.
Giovanna PetrellaDepartment of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Stefano CascinuDepartment of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Oreste Davide GentiliniBreast Surgery Unit, IRCCS San Raffaele Hospital, Milan, Italy.
Giampaolo BianchiniBreast Cancer Group, Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.ORCID 0000-0002-6790-6267
Vita-Salute San Raffaele University · ITIstituto di Ricovero e Cura a Carattere Scientifico San RaffaeleIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

Associazione Italiana per la Ricerca sul Cancro ID 21787
6 · The paper itself

Abstract

Northern Italy has been one of the European regions reporting the highest number of COVID-19 cases and deaths. The pandemic spread has challenged the National Health System, requiring reallocation of most of the available health care resources to treat COVID-19-positive patients, generating a competition with other health care needs, including cancer. Patients with cancer are at higher risk of developing critical illness after COVID-19 infection. Thus, mitigation strategies should be adopted to reduce the likelihood of infection in all patients with cancer. At the same time, suboptimal care and treatments may result in worse cancer-related outcome. In this article, we attempt to estimate the individual risk-benefit balance to define personalized strategies for optimal breast cancer management, avoiding as much as possible a general untailored approach. We discuss and report the strategies our Breast Unit adopted from the beginning of the COVID-19 outbreak to ensure the continuum of the best possible cancer care for our patients while mitigating the risk of infection, despite limited health care resources. IMPLICATIONS FOR PRACTICE: Managing patients with breast cancer during the COVID-19 outbreak is challenging. The present work highlights the need to estimate the individual patient risk of infection, which depends on both epidemiological considerations and individual clinical characteristics. The management of patients with breast cancer should be adapted and personalized according to the balance between COVID-19-related risk and the expected benefit of treatments. This work also provides useful suggestions on the modality of patient triage, the conduct of clinical trials, the management of an oncologic team, and the approach to patients' and health workers' psychological distress.

Indexed as

AdultAgedAge FactorsBetacoronavirusBreast NeoplasmsClinical Trials as TopicContinuity of Patient CareCoronavirus InfectionsCOVID-19FemaleHumansInfection ControlItalyMedical OncologyMiddle AgedPandemicsBreast cancerCOVID-19SARS-CoV-2Treatment

Identifiers

PMID32412693
PMCPMC7272798
OpenAlexW3025085972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.